Medical bioremediation: Prospects for the application of microbial catabolic diversity to aging and several major age-related diseases

Several major diseases of old age, including atherosclerosis, macular degeneration and neurodegenerative diseases are associated with the intracellular accumulation of substances that impair cellular function and viability. Moreover, the accumulation of lipofuscin, a substance that may have similarly deleterious effects, is one of the most universal markers of aging in postmitotic cells. Reversing this accumulation may thus be valuable, but has proven challenging, doubtless because substances resistant to cellular catabolism are inherently hard to degrade. We suggest a radically new approach: augmenting humans' natural catabolic machinery with microbial enzymes. Many recalcitrant organic molecules are naturally degraded in the soil. Since the soil in certain environments - graveyards, for example - is enriched in human remains but does not accumulate these substances, it presumably harbours microbes that degrade them. The enzymes responsible could be identified and engineered to metabolise these substances in vivo. Here, we survey a range of such substances, their putative roles in age-related diseases and the possible benefits of their removal. We discuss how microbes capable of degrading them can be isolated, characterised and their relevant enzymes engineered for this purpose and ways to avoid potential side-effects.

[1]  U. Brunk,et al.  Lipofuscin: mechanisms of age-related accumulation and influence on cell function. , 2002, Free radical biology & medicine.

[2]  M. Baumann,et al.  A mutation in the ovine cathepsin D gene causes a congenital lysosomal storage disease with profound neurodegeneration , 2000, The EMBO journal.

[3]  H. K. KING,et al.  The Chemical Activities of Bacteria , 1948, Nature.

[4]  B. Bahr,et al.  Lysosomal Activation Is a Compensatory Response Against Protein Accumulation and Associated Synaptopathogenesis—An Approach for Slowing Alzheimer Disease? , 2003, Journal of neuropathology and experimental neurology.

[5]  B. Ghetti,et al.  Neurofibrillary tangles in Niemann-Pick disease type C , 2004, Acta Neuropathologica.

[6]  T. Peters,et al.  LYSOSOMES OF THE ARTERIAL WALL , 1972, The Journal of experimental medicine.

[7]  W. Sly,et al.  Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Jockusch,et al.  A2E-epoxides Damage DNA in Retinal Pigment Epithelial Cells , 2003, The Journal of Biological Chemistry.

[9]  J. Sparrow,et al.  DNA is a target of the photodynamic effects elicited in A2E-laden RPE by blue-light illumination. , 2003, Investigative ophthalmology & visual science.

[10]  H. Mandel,et al.  Macrophage uptake of oxidized LDL inhibits lysosomal sphingomyelinase, thus causing the accumulation of unesterified cholesterol-sphingomyelin-rich particles in the lysosomes. A possible role for 7-Ketocholesterol. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[11]  L. Feeney-Burns,et al.  Aging human RPE: morphometric analysis of macular, equatorial, and peripheral cells. , 1984, Investigative ophthalmology & visual science.

[12]  A. Cuervo Autophagy: in sickness and in health. , 2004, Trends in cell biology.

[13]  Ulf T. Brunk,et al.  Serial review: oxidative stress and agingLipofuscin: mechanisms of age-related accumulation and influence on cell function12 , 2002 .

[14]  A. D. de Grey A proposed refinement of the mitochondrial free radical theory of aging. , 1997, BioEssays : news and reviews in molecular, cellular and developmental biology.

[15]  M. Boulton,et al.  The role of the retinal pigment epithelium: Topographical variation and ageing changes , 2001, Eye.

[16]  D. Stover,et al.  Mechanisms and kinetics of procathepsin D activation. , 1999, European journal of biochemistry.

[17]  M. Brown,et al.  Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. , 1983, Annual review of biochemistry.

[18]  Rainer Duden,et al.  Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. , 2002, Human molecular genetics.

[19]  J. Vance,et al.  The Deacetylase HDAC6 Regulates Aggresome Formation and Cell Viability in Response to Misfolded Protein Stress , 2003, Cell.

[20]  D. F. Moore,et al.  Enzyme replacement therapy in Fabry disease: a randomized controlled trial. , 2001, JAMA.

[21]  P. Yancey,et al.  The Role of Microscopy in Understanding Atherosclerotic Lysosomal Lipid Metabolism , 2003, Microscopy and Microanalysis.

[22]  C. H. Werkman Bacterial Metabolism (2nd ed.) , 1940 .

[23]  Brian M. Suzuki,et al.  Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  W. Jerome,et al.  Early atherogenesis in White Carneau pigeons: effect of a short-term regression diet. , 1990, Experimental and molecular pathology.

[25]  J. Buxbaum,et al.  Aβ localization in abnormal endosomes: association with earliest Aβ elevations in AD and Down syndrome , 2004, Neurobiology of Aging.

[26]  Marco A Zarbin,et al.  Current concepts in the pathogenesis of age-related macular degeneration. , 2004, Archives of ophthalmology.

[27]  R. Nixon Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases , 2005, Neurobiology of Aging.

[28]  P. F. Hudak,et al.  Alternatives for Ground Water Cleanup , 1995 .

[29]  P. Libby Do vascular wall cytokines promote atherogenesis? , 1992, Hospital practice.

[30]  Catecholamines and protein deposition in Parkinson's and Alzheimer's disease: old medicine, new targets. , 2004, Rejuvenation research.

[31]  Koji Nakanishi,et al.  Involvement of oxidative mechanisms in blue-light-induced damage to A2E-laden RPE. , 2002, Investigative ophthalmology & visual science.

[32]  Francesco Scaravilli,et al.  Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease , 2004, Nature Genetics.

[33]  R. Nixon Niemann-Pick Type C disease and Alzheimer's disease: the APP-endosome connection fattens up. , 2004, The American journal of pathology.

[34]  J. Cooper Progress towards understanding the neurobiology of Batten disease or neuronal ceroid lipofuscinosis , 2003, Current opinion in neurology.

[35]  S. Kornfeld,et al.  Mannose 6-phosphate receptors: new twists in the tale , 2003, Nature Reviews Molecular Cell Biology.

[36]  Leonidas Stefanis,et al.  Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. , 2004, Science.

[37]  M. Nakano,et al.  Accumulation of cardiac lipofuscin in crab-eating monkeys (Macaca fasicularis): The same rate of lipofuscin accumulation in several species of primates , 1993, Mechanisms of Ageing and Development.

[38]  W. J. Johnson,et al.  Lysosomal metabolism of lipids. , 1996, Sub-cellular biochemistry.

[39]  P. Shah,et al.  Pathophysiology of plaque rupture and the concept of plaque stabilization. , 1996, Cardiology clinics.

[40]  S. Parthasarathy,et al.  Macrophage-derived foam cells freshly isolated from rabbit atherosclerotic lesions degrade modified lipoproteins, promote oxidation of low-density lipoproteins, and contain oxidation-specific lipid-protein adducts. , 1991, The Journal of clinical investigation.

[41]  H. Hoff,et al.  Lipoproteins Containing Apo B Extracted from Human Aortas Structure and Function a , 1985, Annals of the New York Academy of Sciences.

[42]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[43]  R. Brady,et al.  Lectin-specific targeting of beta-glucocerebrosidase to different liver cells via glycosylated liposomes. , 1985, Biochemical medicine.

[44]  C. Finch,et al.  Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[45]  G. Hoppe,et al.  Phospholipids in oxidized low density lipoproteins perturb the ability of macrophages to degrade internalized macromolecules and reduce intracellular cathepsin B activity. , 2003, Atherosclerosis.

[46]  C K Dorey,et al.  Age-related accumulation and spatial distribution of lipofuscin in RPE of normal subjects. , 2001, Investigative ophthalmology & visual science.

[47]  R. Brady,et al.  Gene transfer into the central nervous system in vivo using a recombinanat lentivirus vector , 2002, Journal of neuroscience research.

[48]  J. Guyton,et al.  Development of the atherosclerotic core region. Chemical and ultrastructural analysis of microdissected atherosclerotic lesions from human aorta. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[49]  C. Glabe Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer’s disease , 2001, Journal of Molecular Neuroscience.

[50]  D. Greaves,et al.  Atherosclerosis: role of chemokines and macrophages , 2001, Expert Reviews in Molecular Medicine.

[51]  Daniel J Klionsky,et al.  Development by self-digestion: molecular mechanisms and biological functions of autophagy. , 2004, Developmental cell.

[52]  J. Strong,et al.  The natural history of atherosclerosis; comparison of the early aortic lesions in New Orleans, Guatemala, and Costa Rica. , 1958, The American journal of pathology.

[53]  K. Nakanishi,et al.  Biosynthetic Studies of A2E, a Major Fluorophore of Retinal Pigment Epithelial Lipofuscin* , 2002, The Journal of Biological Chemistry.

[54]  T. Ohm,et al.  Cholesterol and Tau Protein - Findings in Alzheimer’s and Niemann Pick C’s Disease , 2003, Pharmacopsychiatry.

[55]  W D Wagner,et al.  A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[56]  J. Kopitz,et al.  Inhibition of the ATP‐driven proton pump in RPE lysosomes by the major lipofuscin fluorophore A2‐E may contribute to the pathogenesis of age‐related macular degeneration , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[57]  P. Saftig,et al.  At the acidic edge: emerging functions for lysosomal membrane proteins. , 2003, Trends in cell biology.

[58]  M. Mattson Pathways towards and away from Alzheimer's disease , 2004, Nature.

[59]  A. Cuervo Autophagy and aging--when "all you can eat" is yourself. , 2003, Science of aging knowledge environment : SAGE KE.

[60]  J. Wood,et al.  Protein aggregation in motor neurone disorders , 2003, Neuropathology and applied neurobiology.

[61]  L. Notterpek,et al.  Emerging Role for Autophagy in the Removal of Aggresomes in Schwann Cells , 2003, The Journal of Neuroscience.

[62]  Ralph A. Nixon,et al.  Extensive Involvement of Autophagy in Alzheimer Disease: An Immuno-Electron Microscopy Study , 2005, Journal of neuropathology and experimental neurology.

[63]  M. Madigan,et al.  Brock Biology of Microorganisms , 1996 .

[64]  A. Matsuura,et al.  Acidification of vacuoles is required for autophagic degradation in the yeast, Saccharomyces cerevisiae. , 1997, Journal of biochemistry.

[65]  R. Erickson,et al.  Understanding Niemann-Pick type C disease: a fat problem , 2003, Current opinion in neurology.

[66]  E. F. Gale The chemical activities of bacteria , 1948 .

[67]  T. Steck,et al.  Dynamics of lysosomal cholesterol in Niemann-Pick type C and normal human fibroblasts. , 2002, Journal of lipid research.

[68]  D. Schenk Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning , 2002, Nature Reviews Neuroscience.

[69]  R. Brady,et al.  The Niemann-Pick C lesion and its relationship to the intracellular distribution and utilization of LDL cholesterol. , 1994, Biochimica et biophysica acta.

[70]  P. Greengard,et al.  Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. , 2002, The American journal of pathology.

[71]  D. Brooks,et al.  Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. , 2003, Trends in molecular medicine.

[72]  S. Jockusch,et al.  Formation of a nonaoxirane from A2E, a lipofuscin fluorophore related to macular degeneration, and evidence of singlet oxygen involvement. , 2002, Angewandte Chemie.

[73]  Dice Jf Peptide sequences that target cytosolic proteins for lysosomal proteolysis , 1990 .

[74]  L. Liscum,et al.  Intracellular cholesterol transport. , 1992, Journal of lipid research.

[75]  Simon Lovestone,et al.  Alzheimer's disease – do tauists and baptists finally shake hands? , 2002, Trends in Neurosciences.

[76]  Ana Maria Cuervo,et al.  Pathophysiology of chaperone-mediated autophagy. , 2004, The international journal of biochemistry & cell biology.

[77]  R. Stocker,et al.  Lipid oxidation in atherogenesis: an overview. , 2004, Biochemical Society transactions.

[78]  J. Archer,et al.  Construction of Rhodococcus random mutagenesis libraries using Tn5 transposition complexes. , 2001, Microbiology.

[79]  K. Nakanishi,et al.  Isolation and one-step preparation of A2E and iso-A2E, fluorophores from human retinal pigment epithelium. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[80]  D. Steinberg,et al.  Enhanced Macrophage Uptake of Low Density Lipoprotein after Self‐Aggregation , 1988, Arteriosclerosis.

[81]  A. D. de Grey Bioremediation meets biomedicine: therapeutic translation of microbial catabolism to the lysosome. , 2002, Trends in biotechnology.

[82]  J. Buxbaum,et al.  Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. , 2004, Neurobiology of aging.

[83]  J. August,et al.  Reconstitution of the lysosomal proton pump. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[84]  J L Witztum,et al.  Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. , 1989, The Journal of clinical investigation.

[85]  J. Lemontt,et al.  Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[86]  K. Nakanishi,et al.  A2E, a lipofuscin fluorophore, in human retinal pigmented epithelial cells in culture. , 1999, Investigative ophthalmology & visual science.

[87]  P. Mccarty,et al.  Environmental Biotechnology: Principles and Applications , 2000 .

[88]  S. Tsuji,et al.  Expanded polyglutamine stretches form an ‘aggresome’ , 2002, Neuroscience Letters.

[89]  U. Bickel,et al.  Delivery of peptides and proteins through the blood-brain barrier. , 1993, Advanced drug delivery reviews.

[90]  J. Gofman,et al.  Lipoproteins and atherosclerosis. , 1951, Journal of gerontology.

[91]  P. Yancey,et al.  Lysosomal cholesterol derived from mildly oxidized low density lipoprotein is resistant to efflux. , 2001, Journal of lipid research.

[92]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[93]  W. J. Johnson,et al.  Lipoproteins and cellular cholesterol homeostasis. , 1997, Sub-cellular biochemistry.

[94]  U. Steinbrecher,et al.  Cholesterol delivered to macrophages by oxidized low density lipoprotein is sequestered in lysosomes and fails to efflux normally. , 2000, Journal of lipid research.

[95]  K. G. Coleman,et al.  Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. , 1997, Science.

[96]  H. Kimelberg,et al.  Electrophysiologically “complex” glial cells freshly isolated from the hippocampus are immunopositive for the chondroitin sulfate proteoglycan NG2 , 2003, Journal of neuroscience research.

[97]  R. Mahley,et al.  Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. , 1999, Current opinion in lipidology.

[98]  He-Jin Lee,et al.  Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[99]  L. Rudel,et al.  2 Lipoproteins and atherosclerosis , 1987 .

[100]  R. Vonderheide Telomerase as a universal tumor-associated antigen for cancer immunotherapy , 2002, Oncogene.

[101]  R. Brady,et al.  Gaucher and Fabry diseases: from understanding pathophysiology to rational therapies , 2003, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[102]  B. Friguet,et al.  Are expanded polyglutamine proteins a proteasome substrate? , 2004, Rejuvenation research.

[103]  K. Nakanishi,et al.  The lipofuscin fluorophore A2E mediates blue light-induced damage to retinal pigmented epithelial cells. , 2000, Investigative ophthalmology & visual science.

[104]  J. Wegiel,et al.  Contribution of glial cells to the development of amyloid plaques in Alzheimer’s disease , 2004, Neurobiology of Aging.

[105]  T. Yoshimori Autophagy: a regulated bulk degradation process inside cells. , 2004, Biochemical and biophysical research communications.

[106]  B. Shastry Neurodegenerative disorders of protein aggregation , 2003, Neurochemistry International.

[107]  J. Dice,et al.  Peptide sequences that target cytosolic proteins for lysosomal proteolysis. , 1990, Trends in biochemical sciences.

[108]  M. Sands,et al.  Human CD34+ hematopoietic progenitor cell-directed lentiviral-mediated gene therapy in a xenotransplantation model of lysosomal storage disease. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[109]  K. Nakanishi,et al.  A2E, a byproduct of the visual cycle , 2003, Vision Research.